🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ray Dalio’s MEDP Holdings & Trades

First Buy
Q3 2025
Duration Held
3 Quarters
Largest Add
Q3 2025
+33,230 Shares
Current Position
41,135 Shares
$19.75 M Value

Ray Dalio's MEDP Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 41,135 shares of Medpace Holdings, Inc. (MEDP) worth $19.75 M, representing 0.09% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.

Based on 13F filings, Ray Dalio has maintained this position in MEDP for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 6,833 shares.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Medpace Holdings (MEDP) Holding Value Over Time

Track share changes against reported price movement

Quarterly Medpace Holdings (MEDP) Trades by Ray Dalio

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +6,833 Add 19.92% 41,135 $480.19
Q4 2025 +1,072 Add 3.23% 34,302 $561.65
Q3 2025 +33,230 New Buy 33,230 $514.16

Ray Dalio's Medpace Holdings Investment FAQs

Ray Dalio first purchased Medpace Holdings, Inc. (MEDP) in Q3 2025, acquiring 33,230 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Medpace Holdings, Inc. (MEDP) for 3 quarters since Q3 2025.

Ray Dalio's largest addition to Medpace Holdings, Inc. (MEDP) was in Q3 2025, adding 33,230 shares worth $17.09 M.

According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 41,135 shares of Medpace Holdings, Inc. (MEDP), valued at approximately $19.75 M.

As of the Q1 2026 filing, Medpace Holdings, Inc. (MEDP) represents approximately 0.09% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.

Ray Dalio's peak holding in Medpace Holdings, Inc. (MEDP) was 41,135 shares, as reported at the end of Q1 2026.